Structural and virological identification of neutralizing antibody footprint provides insights into therapeutic antibody design against SARS-CoV-2 variants

Medical treatments using potent neutralizing SARS-CoV-2 antibodies have achieved remarkable improvements in clinical symptoms, changing the situation for the severity of COVID-19 patients. We previously reported an antibody, NT-108 with potent neutralizing activity. However, the structural and funct...

Full description

Saved in:
Bibliographic Details
Published inCommunications biology Vol. 8; no. 1; pp. 483 - 12
Main Authors Anraku, Yuki, Kita, Shunsuke, Onodera, Taishi, Sato, Akihiko, Tadokoro, Takashi, Ito, Shiori, Adachi, Yu, Kotaki, Ryutaro, Suzuki, Tateki, Sasaki, Jiei, Shiwa-Sudo, Nozomi, Iwata-Yoshikawa, Naoko, Nagata, Noriyo, Kobayashi, Souta, Kazuki, Yasuhiro, Oshimura, Mitsuo, Nomura, Takao, Sasaki, Michihito, Orba, Yasuko, Suzuki, Tadaki, Sawa, Hirofumi, Hashiguchi, Takao, Fukuhara, Hideo, Takahashi, Yoshimasa, Maenaka, Katsumi
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 22.03.2025
Nature Publishing Group
Nature Portfolio
Subjects
631/326/596/4130
631/535/1258/1259
631/535/1266
631/61/51/2318
82/1
82/103
ACE2
Angiotensin-Converting Enzyme 2
Animals
Antibodies
Antibodies, Neutralizing - chemistry
Antibodies, Neutralizing - immunology
Antibodies, Neutralizing - therapeutic use
Antibodies, Viral - chemistry
Antibodies, Viral - immunology
Antibodies, Viral - therapeutic use
Biomedical and Life Sciences
COVID-19
COVID-19 - immunology
COVID-19 - therapy
COVID-19 - virology
COVID-19 Drug Treatment
Cricetinae
Cryoelectron Microscopy
Humans
Life Sciences
Medical treatment
Mesocricetus
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
Severe acute respiratory syndrome coronavirus 2
Spike Glycoprotein, Coronavirus - chemistry
Spike Glycoprotein, Coronavirus - genetics
Spike Glycoprotein, Coronavirus - immunology
Structure-function relationships
Online AccessGet full text

Cover

Abstract Medical treatments using potent neutralizing SARS-CoV-2 antibodies have achieved remarkable improvements in clinical symptoms, changing the situation for the severity of COVID-19 patients. We previously reported an antibody, NT-108 with potent neutralizing activity. However, the structural and functional basis for the neutralizing activity of NT-108 has not yet been understood. Here, we demonstrated the therapeutic effects of NT-108 in a hamster model and its protective effects at low doses. Furthermore, we determined the cryo-EM structure of NT-108 in complex with SARS-CoV-2 spike. The single-chain Fv construction of NT-108 improved the cryo-EM maps because of the prevention of preferred orientations induced by Fab orientation. The footprints of NT-108 illuminated how escape mutations such as E484K evade from class 2 antibody recognition without ACE2 affinity attenuation. The functional and structural basis for the potent neutralizing activity of NT-108 provides insights into the rational design of therapeutic antibodies. A SARS-CoV-2 antibody, NT-108, exhibits potent therapeutic effects in vivo. Cryo-EM structure of the spike complexed with single-chain Fv of NT108 reveals its neutralizing mechanism, providing insight into antibody therapeutic design.
AbstractList Medical treatments using potent neutralizing SARS-CoV-2 antibodies have achieved remarkable improvements in clinical symptoms, changing the situation for the severity of COVID-19 patients. We previously reported an antibody, NT-108 with potent neutralizing activity. However, the structural and functional basis for the neutralizing activity of NT-108 has not yet been understood. Here, we demonstrated the therapeutic effects of NT-108 in a hamster model and its protective effects at low doses. Furthermore, we determined the cryo-EM structure of NT-108 in complex with SARS-CoV-2 spike. The single-chain Fv construction of NT-108 improved the cryo-EM maps because of the prevention of preferred orientations induced by Fab orientation. The footprints of NT-108 illuminated how escape mutations such as E484K evade from class 2 antibody recognition without ACE2 affinity attenuation. The functional and structural basis for the potent neutralizing activity of NT-108 provides insights into the rational design of therapeutic antibodies.
Medical treatments using potent neutralizing SARS-CoV-2 antibodies have achieved remarkable improvements in clinical symptoms, changing the situation for the severity of COVID-19 patients. We previously reported an antibody, NT-108 with potent neutralizing activity. However, the structural and functional basis for the neutralizing activity of NT-108 has not yet been understood. Here, we demonstrated the therapeutic effects of NT-108 in a hamster model and its protective effects at low doses. Furthermore, we determined the cryo-EM structure of NT-108 in complex with SARS-CoV-2 spike. The single-chain Fv construction of NT-108 improved the cryo-EM maps because of the prevention of preferred orientations induced by Fab orientation. The footprints of NT-108 illuminated how escape mutations such as E484K evade from class 2 antibody recognition without ACE2 affinity attenuation. The functional and structural basis for the potent neutralizing activity of NT-108 provides insights into the rational design of therapeutic antibodies. A SARS-CoV-2 antibody, NT-108, exhibits potent therapeutic effects in vivo. Cryo-EM structure of the spike complexed with single-chain Fv of NT108 reveals its neutralizing mechanism, providing insight into antibody therapeutic design.
Medical treatments using potent neutralizing SARS-CoV-2 antibodies have achieved remarkable improvements in clinical symptoms, changing the situation for the severity of COVID-19 patients. We previously reported an antibody, NT-108 with potent neutralizing activity. However, the structural and functional basis for the neutralizing activity of NT-108 has not yet been understood. Here, we demonstrated the therapeutic effects of NT-108 in a hamster model and its protective effects at low doses. Furthermore, we determined the cryo-EM structure of NT-108 in complex with SARS-CoV-2 spike. The single-chain Fv construction of NT-108 improved the cryo-EM maps because of the prevention of preferred orientations induced by Fab orientation. The footprints of NT-108 illuminated how escape mutations such as E484K evade from class 2 antibody recognition without ACE2 affinity attenuation. The functional and structural basis for the potent neutralizing activity of NT-108 provides insights into the rational design of therapeutic antibodies.A SARS-CoV-2 antibody, NT-108, exhibits potent therapeutic effects in vivo. Cryo-EM structure of the spike complexed with single-chain Fv of NT108 reveals its neutralizing mechanism, providing insight into antibody therapeutic design.
Medical treatments using potent neutralizing SARS-CoV-2 antibodies have achieved remarkable improvements in clinical symptoms, changing the situation for the severity of COVID-19 patients. We previously reported an antibody, NT-108 with potent neutralizing activity. However, the structural and functional basis for the neutralizing activity of NT-108 has not yet been understood. Here, we demonstrated the therapeutic effects of NT-108 in a hamster model and its protective effects at low doses. Furthermore, we determined the cryo-EM structure of NT-108 in complex with SARS-CoV-2 spike. The single-chain Fv construction of NT-108 improved the cryo-EM maps because of the prevention of preferred orientations induced by Fab orientation. The footprints of NT-108 illuminated how escape mutations such as E484K evade from class 2 antibody recognition without ACE2 affinity attenuation. The functional and structural basis for the potent neutralizing activity of NT-108 provides insights into the rational design of therapeutic antibodies.Medical treatments using potent neutralizing SARS-CoV-2 antibodies have achieved remarkable improvements in clinical symptoms, changing the situation for the severity of COVID-19 patients. We previously reported an antibody, NT-108 with potent neutralizing activity. However, the structural and functional basis for the neutralizing activity of NT-108 has not yet been understood. Here, we demonstrated the therapeutic effects of NT-108 in a hamster model and its protective effects at low doses. Furthermore, we determined the cryo-EM structure of NT-108 in complex with SARS-CoV-2 spike. The single-chain Fv construction of NT-108 improved the cryo-EM maps because of the prevention of preferred orientations induced by Fab orientation. The footprints of NT-108 illuminated how escape mutations such as E484K evade from class 2 antibody recognition without ACE2 affinity attenuation. The functional and structural basis for the potent neutralizing activity of NT-108 provides insights into the rational design of therapeutic antibodies.
Abstract Medical treatments using potent neutralizing SARS-CoV-2 antibodies have achieved remarkable improvements in clinical symptoms, changing the situation for the severity of COVID-19 patients. We previously reported an antibody, NT-108 with potent neutralizing activity. However, the structural and functional basis for the neutralizing activity of NT-108 has not yet been understood. Here, we demonstrated the therapeutic effects of NT-108 in a hamster model and its protective effects at low doses. Furthermore, we determined the cryo-EM structure of NT-108 in complex with SARS-CoV-2 spike. The single-chain Fv construction of NT-108 improved the cryo-EM maps because of the prevention of preferred orientations induced by Fab orientation. The footprints of NT-108 illuminated how escape mutations such as E484K evade from class 2 antibody recognition without ACE2 affinity attenuation. The functional and structural basis for the potent neutralizing activity of NT-108 provides insights into the rational design of therapeutic antibodies.
ArticleNumber 483
Author Hashiguchi, Takao
Onodera, Taishi
Tadokoro, Takashi
Adachi, Yu
Nagata, Noriyo
Maenaka, Katsumi
Iwata-Yoshikawa, Naoko
Kotaki, Ryutaro
Shiwa-Sudo, Nozomi
Fukuhara, Hideo
Kazuki, Yasuhiro
Sasaki, Jiei
Suzuki, Tadaki
Kita, Shunsuke
Nomura, Takao
Kobayashi, Souta
Anraku, Yuki
Sasaki, Michihito
Oshimura, Mitsuo
Takahashi, Yoshimasa
Sato, Akihiko
Suzuki, Tateki
Ito, Shiori
Orba, Yasuko
Sawa, Hirofumi
Author_xml – sequence: 1
  givenname: Yuki
  orcidid: 0000-0002-5731-0902
  surname: Anraku
  fullname: Anraku, Yuki
  organization: Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University
– sequence: 2
  givenname: Shunsuke
  orcidid: 0000-0003-3969-302X
  surname: Kita
  fullname: Kita, Shunsuke
  email: kita@pharm.hokudai.ac.jp
  organization: Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University
– sequence: 3
  givenname: Taishi
  surname: Onodera
  fullname: Onodera, Taishi
  organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases
– sequence: 4
  givenname: Akihiko
  surname: Sato
  fullname: Sato, Akihiko
  organization: Laboratory for Drug Discovery & Disease Research, Shionogi & Co., Ltd., Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University
– sequence: 5
  givenname: Takashi
  surname: Tadokoro
  fullname: Tadokoro, Takashi
  organization: Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University
– sequence: 6
  givenname: Shiori
  surname: Ito
  fullname: Ito, Shiori
  organization: Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University
– sequence: 7
  givenname: Yu
  surname: Adachi
  fullname: Adachi, Yu
  organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases
– sequence: 8
  givenname: Ryutaro
  orcidid: 0000-0001-7965-1671
  surname: Kotaki
  fullname: Kotaki, Ryutaro
  organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases
– sequence: 9
  givenname: Tateki
  surname: Suzuki
  fullname: Suzuki, Tateki
  organization: Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University
– sequence: 10
  givenname: Jiei
  surname: Sasaki
  fullname: Sasaki, Jiei
  organization: Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University
– sequence: 11
  givenname: Nozomi
  surname: Shiwa-Sudo
  fullname: Shiwa-Sudo, Nozomi
  organization: Department of Pathology, National Institute of Infectious Diseases
– sequence: 12
  givenname: Naoko
  surname: Iwata-Yoshikawa
  fullname: Iwata-Yoshikawa, Naoko
  organization: Department of Pathology, National Institute of Infectious Diseases
– sequence: 13
  givenname: Noriyo
  surname: Nagata
  fullname: Nagata, Noriyo
  organization: Department of Pathology, National Institute of Infectious Diseases
– sequence: 14
  givenname: Souta
  surname: Kobayashi
  fullname: Kobayashi, Souta
  organization: Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University
– sequence: 15
  givenname: Yasuhiro
  surname: Kazuki
  fullname: Kazuki, Yasuhiro
  organization: Chromosome Engineering Research Center, Tottori University, Department of Chromosome Biomedical Engineering, School of Life Science, Faculty of Medicine, Tottori University
– sequence: 16
  givenname: Mitsuo
  surname: Oshimura
  fullname: Oshimura, Mitsuo
  organization: Trans Chromosomics Inc
– sequence: 17
  givenname: Takao
  surname: Nomura
  fullname: Nomura, Takao
  organization: Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University
– sequence: 18
  givenname: Michihito
  surname: Sasaki
  fullname: Sasaki, Michihito
  organization: Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University
– sequence: 19
  givenname: Yasuko
  surname: Orba
  fullname: Orba, Yasuko
  organization: Division of Molecular Pathobiology, International Institute for Zoonosis Control, Hokkaido University, Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, One Health Research Center, Hokkaido University, International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University
– sequence: 20
  givenname: Tadaki
  orcidid: 0000-0002-3820-9542
  surname: Suzuki
  fullname: Suzuki, Tadaki
  organization: Department of Pathology, National Institute of Infectious Diseases
– sequence: 21
  givenname: Hirofumi
  orcidid: 0000-0003-2569-2755
  surname: Sawa
  fullname: Sawa, Hirofumi
  organization: Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, One Health Research Center, Hokkaido University, International Collaboration Unit, International Institute for Zoonosis Control, Hokkaido University, Global Virus Network
– sequence: 22
  givenname: Takao
  orcidid: 0000-0001-7578-7571
  surname: Hashiguchi
  fullname: Hashiguchi, Takao
  organization: Laboratory of Medical Virology, Institute for Life and Medical Sciences, Kyoto University, CREST, Japan Science and Technology Agency, Kyoto University Immunomonitoring Center, Kyoto University
– sequence: 23
  givenname: Hideo
  surname: Fukuhara
  fullname: Fukuhara, Hideo
  organization: Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Division of Pathogen Structure, International Institute for Zoonosis Control, Hokkaido University
– sequence: 24
  givenname: Yoshimasa
  orcidid: 0000-0001-6342-4087
  surname: Takahashi
  fullname: Takahashi, Yoshimasa
  email: ytakahas@niid.go.jp
  organization: Research Center for Drug and Vaccine Development, National Institute of Infectious Diseases, Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University
– sequence: 25
  givenname: Katsumi
  orcidid: 0000-0002-5459-521X
  surname: Maenaka
  fullname: Maenaka, Katsumi
  email: maenaka@pharm.hokudai.ac.jp
  organization: Laboratory of Biomolecular Science, and Center for Research and Education on Drug Discovery, Faculty of Pharmaceutical Sciences, Hokkaido University, Institute for Vaccine Research and Development (HU-IVReD), Hokkaido University, One Health Research Center, Hokkaido University, Division of Pathogen Structure, International Institute for Zoonosis Control, Hokkaido University, Global Station for Biosurfaces and Drug Discovery, Hokkaido University, Faculty of Pharmaceutical Sciences, Kyushu University
BackLink https://www.ncbi.nlm.nih.gov/pubmed/40121330$$D View this record in MEDLINE/PubMed
BookMark eNp9kstu1DAUhiNUREvpC7BAltiwCfiWOF6hasSlUiUkBthaviXjUcYebGek8iq8LM6k9MKClY9Pvv_Pycn_vDrxwduqeongWwRJ9y5RDCGpIW5qyDrMavikOsOE85q0FJ88qE-ri5S2EELEOW8JfVadUogwIgSeVb_XOU46T1GOQHoDDi6GMQxOl7sz1mfXlzq74EHogbdTLqT75fxQ8OxUMDegDyHvo_MZ7GM4FFUCzic3bPJc5ADyxka5L1qn71UFc4MHcpAFzmB9-XVdr8KPGoODjK5g6UX1tJdjshe353n1_eOHb6vP9fWXT1ery-taU05zrVEnG6Q7qzCzuIFYNR1jveS6NCjTquFUdgxJ2DJltCItN7SRylDbKKUYOa-uFl8T5FaUL9nJeCOCdOLYCHEQMpbZRysgbDiBzBhFNdU9kmW_mre9kcRqBmev94vXflI7a3TZYFnYI9PHT7zbiCEcBEIc867pisObW4cYfk42ZbFzSdtxlN6GKQmCOth2LSRtQV__g27DFH3Z1ZHCbUPRPNKrhyPdzfI3BAXAC6BjSCna_g5BUMxhE0vYRAmbOIZNzCKyiNL86wcb79_9H9Uf3j_a4w
Cites_doi 10.1038/s41467-020-20314-w
10.1038/s41467-022-29421-2
10.1126/science.abb7269
10.1038/s42003-019-0437-z
10.1128/JVI.01110-21
10.1002/pro.3235
10.1371/journal.ppat.1009233
10.1038/s41579-020-00459-7
10.1038/s41467-021-21609-2
10.1038/s41586-022-04594-4
10.1016/j.virusres.2006.01.017
10.1038/nmeth.4193
10.1016/j.jim.2007.09.017
10.1016/j.cell.2020.08.012
10.1038/s41467-023-39890-8
10.1016/j.jmb.2007.05.022
10.1016/S0140-6736(20)30183-5
10.1016/j.celrep.2021.109433
10.1073/pnas.1218256109
10.1016/j.cell.2020.02.052
10.1107/S2059798318006496
10.1107/S0907444910007493
10.1016/j.cell.2021.04.033
10.7554/eLife.42166
10.3390/v15112153
10.1056/NEJMoa2001017
10.1111/1348-0421.12945
10.1016/j.cell.2020.09.037
10.1016/j.chom.2021.02.003
10.1038/s41579-020-00468-6
10.1038/s41592-022-01488-1
10.1016/j.jmb.2021.167177
10.1107/S0907444910045749
10.1038/s41586-021-03398-2
10.1021/acscentsci.1c00804
10.1038/s41467-019-11821-6
10.1038/s41586-020-2349-y
10.1016/S0140-6736(20)30211-7
10.1038/s41586-020-2180-5
10.1038/s41586-021-04385-3
10.1016/0378-1119(91)90434-D
10.1038/s41586-022-04980-y
10.1073/pnas.2002589117
10.1016/j.chom.2022.10.003
10.1016/j.celrep.2021.109109
10.1126/science.abd0827
10.1016/j.jsb.2015.08.008
10.1111/febs.14991
10.1038/s41467-020-15562-9
10.1016/j.cell.2020.10.030
10.1038/s41586-020-2772-0
10.1016/j.immuni.2021.08.025
10.1038/s41586-020-2012-7
10.1038/nmeth.4347
10.1016/j.chom.2020.06.010
10.1038/nmeth.4169
10.1038/s41422-020-00444-y
10.1038/s41586-020-2852-1
10.1093/bioinformatics/btaa739
10.1107/S0907444909047374
10.1038/s41591-021-01294-w
10.1038/s41586-020-2381-y
10.1128/JCM.01736-21
10.1038/s42003-022-03739-5
10.1016/j.immuni.2021.06.015
10.1107/S2059798319011471
10.1371/journal.ppat.1009772
10.1107/S0907444905036693
10.1126/science.abb2507
10.1038/s41589-020-00679-1
10.1002/jcc.20084
10.1002/pro.3330
10.1016/j.str.2023.12.013
10.1038/s41592-023-01769-3
10.1016/j.cell.2021.04.032
10.1126/science.adk8946
10.1126/science.abd0826
ContentType Journal Article
Copyright The Author(s) 2025
2025. The Author(s).
Copyright Nature Publishing Group 2025
The Author(s) 2025 2025
Copyright_xml – notice: The Author(s) 2025
– notice: 2025. The Author(s).
– notice: Copyright Nature Publishing Group 2025
– notice: The Author(s) 2025 2025
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
88I
8FE
8FH
8FK
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
COVID
DWQXO
GNUQQ
HCIFZ
LK8
M2P
M7P
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.1038/s42003-025-07827-0
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
ProQuest Central (purchase pre-March 2016)
Science Database (Alumni Edition)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
Natural Science Collection
ProQuest One Community College
Coronavirus Research Database
ProQuest Central Korea
ProQuest Central Student
SciTech Premium Collection
ProQuest Biological Science Collection
Science Database
Biological Science Database
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Applied & Life Sciences
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
ProQuest One Applied & Life Sciences
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
ProQuest Central (New)
ProQuest Science Journals (Alumni Edition)
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest Science Journals
ProQuest One Academic Eastern Edition
Coronavirus Research Database
Biological Science Database
ProQuest SciTech Collection
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList MEDLINE

Publicly Available Content Database

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: Directory of Open Access Journals (DOAJ)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Biology
EISSN 2399-3642
EndPage 12
ExternalDocumentID oai_doaj_org_article_0059307ddb4c4cf1a642c96fda3ec707
PMC11929858
40121330
10_1038_s42003_025_07827_0
Genre Journal Article
GrantInformation_xml – fundername: Takeda Science Foundation
  grantid: Research grant
  funderid: https://doi.org/10.13039/100007449
– fundername: MEXT | Japan Science and Technology Agency (JST)
  grantid: JPMJCR20H8
  funderid: https://doi.org/10.13039/501100002241
– fundername: Takeda Science Foundation
  grantid: Research grant
– fundername: MEXT | Japan Science and Technology Agency (JST)
  grantid: JPMJCR20H8
GroupedDBID 0R~
53G
88I
AAJSJ
AASML
ABDBF
ABUWG
ACGFS
ACUHS
ADBBV
AFKRA
AJTQC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BBNVY
BCNDV
BENPR
BHPHI
C6C
CCPQU
DWQXO
EBLON
EBS
GNUQQ
GROUPED_DOAJ
HCIFZ
HYE
M2P
M7P
M~E
NAO
O9-
OK1
PGMZT
PHGZT
PIMPY
RNT
RPM
AAYXX
CITATION
PHGZM
SNYQT
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7XB
8FE
8FH
8FK
AARCD
COVID
LK8
PKEHL
PQEST
PQGLB
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c494t-c18a51c8eb27e2502b5877fa9cb2747cb594a871a067bdcb369d45abd4e5bbb73
IEDL.DBID AAJSJ
ISSN 2399-3642
IngestDate Wed Aug 27 01:23:33 EDT 2025
Thu Aug 21 18:40:02 EDT 2025
Thu Jul 10 18:32:49 EDT 2025
Wed Aug 13 11:04:04 EDT 2025
Fri May 16 02:46:38 EDT 2025
Tue Jul 01 05:17:44 EDT 2025
Sun Mar 23 01:28:40 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2025. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c494t-c18a51c8eb27e2502b5877fa9cb2747cb594a871a067bdcb369d45abd4e5bbb73
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0001-7965-1671
0000-0002-5459-521X
0000-0002-3820-9542
0000-0001-6342-4087
0000-0001-7578-7571
0000-0003-2569-2755
0000-0002-5731-0902
0000-0003-3969-302X
OpenAccessLink https://www.nature.com/articles/s42003-025-07827-0
PMID 40121330
PQID 3180265417
PQPubID 4669726
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_0059307ddb4c4cf1a642c96fda3ec707
pubmedcentral_primary_oai_pubmedcentral_nih_gov_11929858
proquest_miscellaneous_3180686036
proquest_journals_3180265417
pubmed_primary_40121330
crossref_primary_10_1038_s42003_025_07827_0
springer_journals_10_1038_s42003_025_07827_0
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2025-03-22
PublicationDateYYYYMMDD 2025-03-22
PublicationDate_xml – month: 03
  year: 2025
  text: 2025-03-22
  day: 22
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Communications biology
PublicationTitleAbbrev Commun Biol
PublicationTitleAlternate Commun Biol
PublicationYear 2025
Publisher Nature Publishing Group UK
Nature Publishing Group
Nature Portfolio
Publisher_xml – name: Nature Publishing Group UK
– name: Nature Publishing Group
– name: Nature Portfolio
References 7827_CR60
S Moriyama (7827_CR54) 2023; 14
D Liebschner (7827_CR75) 2019; 75
J Lan (7827_CR44) 2020; 581
A. G Schmidt (7827_CR65) 2013; 110
P Evans (7827_CR69) 2006; 62
A. E Gorbalenya (7827_CR4) 2006; 117
7827_CR21
S Moriyama (7827_CR28) 2021; 54
Y Cao (7827_CR47) 2023; 614
T Wagner (7827_CR79) 2019; 2
C. J Williams (7827_CR76) 2018; 27
7827_CR29
P Zhou (7827_CR6) 2020; 579
A Punjani (7827_CR81) 2017; 14
N Hitoshi (7827_CR68) 1991; 108
A Rohou (7827_CR78) 2015; 192
P V’kovski (7827_CR7) 2020; 19
A. J Greaney (7827_CR62) 2021; 29
V Yin (7827_CR57) 2021; 7
P Emsley (7827_CR74) 2010; 66
T. D Goddard (7827_CR83) 2018; 27
C Huang (7827_CR1) 2020; 395
M Hoffmann (7827_CR9) 2020; 181
N Zhu (7827_CR5) 2020; 382
7827_CR51
T Ozawa (7827_CR55) 2024; 32
X Yang (7827_CR26) 2022; 13
7827_CR58
7827_CR11
Y Adachi (7827_CR23) 2019; 10
T Onodera (7827_CR22) 2021; 54
T Tadokoro (7827_CR33) 2020; 287
7827_CR18
7827_CR15
W Kabsch (7827_CR70) 2010; 66
M. D Winn (7827_CR71) 2011; 67
D. J Benton (7827_CR36) 2020; 588
D Wrapp (7827_CR37) 2020; 367
H Yao (7827_CR38) 2021; 31
M Mirdita (7827_CR73) 2022; 19
C. O Barnes (7827_CR25) 2020; 588
C Hsieh (7827_CR31) 2020; 369
Q Zhang (7827_CR46) 2021; 12
Y Cao (7827_CR19) 2022; 608
N Chen (7827_CR2) 2020; 395
J. F Scheid (7827_CR40) 2021; 184
I Drulyte (7827_CR50) 2018; 74
V. R Shanker (7827_CR56) 2024; 385
E. F Pettersen (7827_CR82) 2004; 25
X Zhou (7827_CR48) 2021; 35
J Hansen (7827_CR14) 2020; 369
Z Daniloski (7827_CR12) 2021; 184
F Bertoglio (7827_CR35) 2021; 12
P Wang (7827_CR30) 2021; 593
D Asarnow (7827_CR42) 2021; 184
R Li (7827_CR20) 2022; 5
K Gangavarapu (7827_CR59) 2023; 20
R. M Horton (7827_CR67) 1990; 8
S Miersch (7827_CR41) 2021; 433
7827_CR49
J Zivanov (7827_CR80) 2018; 7
S Matsuyama (7827_CR10) 2020; 117
C. J Bracken (7827_CR39) 2021; 17
Y Zi Tan (7827_CR32) 2017; 14
M. I. J Raybould (7827_CR45) 2021; 37
T. N Starr (7827_CR63) 2020; 182
L Piccoli (7827_CR43) 2020; 183
B Hu (7827_CR3) 2021; 19
H Satofuka (7827_CR24) 2022; 13
P Bühler (7827_CR34) 2010; 30
J Huo (7827_CR53) 2020; 28
M Sasaki (7827_CR66) 2021; 17
M Takeda (7827_CR8) 2022; 66
R Shi (7827_CR52) 2020; 584
T Tiller (7827_CR64) 2008; 329
S Iketani (7827_CR17) 2022; 604
M Yuan (7827_CR72) 2020; 368
M Alenquer (7827_CR61) 2021; 17
S. Q Zheng (7827_CR77) 2017; 14
C Wang (7827_CR27) 2021; 12
D Pinto (7827_CR13) 2020; 583
E Krissinel (7827_CR84) 2007; 372
Y Cao (7827_CR16) 2022; 602
References_xml – volume: 12
  start-page: 1
  year: 2021
  ident: 7827_CR27
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-20314-w
– volume: 13
  start-page: 1
  year: 2022
  ident: 7827_CR24
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-022-29421-2
– volume: 368
  start-page: 630
  year: 2020
  ident: 7827_CR72
  publication-title: Science (80-)
  doi: 10.1126/science.abb7269
– volume: 2
  start-page: 1
  year: 2019
  ident: 7827_CR79
  publication-title: Commun. Biol.
  doi: 10.1038/s42003-019-0437-z
– ident: 7827_CR60
  doi: 10.1128/JVI.01110-21
– volume: 27
  start-page: 14
  year: 2018
  ident: 7827_CR83
  publication-title: Protein Sci
  doi: 10.1002/pro.3235
– volume: 8
  start-page: 528
  year: 1990
  ident: 7827_CR67
  publication-title: Biotechniques
– volume: 17
  start-page: 1
  year: 2021
  ident: 7827_CR66
  publication-title: PLoS Pathog
  doi: 10.1371/journal.ppat.1009233
– volume: 19
  start-page: 141
  year: 2021
  ident: 7827_CR3
  publication-title: Nat. Rev. Microbiol.
  doi: 10.1038/s41579-020-00459-7
– ident: 7827_CR49
– volume: 12
  start-page: 1
  year: 2021
  ident: 7827_CR35
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-021-21609-2
– volume: 604
  start-page: 553
  year: 2022
  ident: 7827_CR17
  publication-title: Nature
  doi: 10.1038/s41586-022-04594-4
– volume: 117
  start-page: 17
  year: 2006
  ident: 7827_CR4
  publication-title: Virus Res
  doi: 10.1016/j.virusres.2006.01.017
– volume: 14
  start-page: 331
  year: 2017
  ident: 7827_CR77
  publication-title: Nat. Methods
  doi: 10.1038/nmeth.4193
– volume: 329
  start-page: 112
  year: 2008
  ident: 7827_CR64
  publication-title: J. Immunol. Methods
  doi: 10.1016/j.jim.2007.09.017
– volume: 182
  start-page: 1295
  year: 2020
  ident: 7827_CR63
  publication-title: Cell
  doi: 10.1016/j.cell.2020.08.012
– volume: 14
  start-page: 1
  year: 2023
  ident: 7827_CR54
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-023-39890-8
– volume: 372
  start-page: 774
  year: 2007
  ident: 7827_CR84
  publication-title: J. Mol. Biol.
  doi: 10.1016/j.jmb.2007.05.022
– volume: 395
  start-page: 497
  year: 2020
  ident: 7827_CR1
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30183-5
– ident: 7827_CR51
  doi: 10.1016/j.celrep.2021.109433
– volume: 110
  start-page: 264
  year: 2013
  ident: 7827_CR65
  publication-title: Proc. Natl. Acad. Sci.
  doi: 10.1073/pnas.1218256109
– volume: 181
  start-page: 271
  year: 2020
  ident: 7827_CR9
  publication-title: Cell
  doi: 10.1016/j.cell.2020.02.052
– volume: 74
  start-page: 560
  year: 2018
  ident: 7827_CR50
  publication-title: Acta Crystallogr. Sect. D Struct. Biol.
  doi: 10.1107/S2059798318006496
– volume: 66
  start-page: 486
  year: 2010
  ident: 7827_CR74
  publication-title: Acta Crystallogr. Sect. D Biol. Crystallogr.
  doi: 10.1107/S0907444910007493
– volume: 614
  start-page: 521
  year: 2023
  ident: 7827_CR47
  publication-title: Nature
– volume: 184
  start-page: 3192
  year: 2021
  ident: 7827_CR42
  publication-title: Cell
  doi: 10.1016/j.cell.2021.04.033
– ident: 7827_CR15
– volume: 7
  start-page: 1
  year: 2018
  ident: 7827_CR80
  publication-title: Elife
  doi: 10.7554/eLife.42166
– ident: 7827_CR21
  doi: 10.3390/v15112153
– volume: 382
  start-page: 727
  year: 2020
  ident: 7827_CR5
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa2001017
– volume: 66
  start-page: 15
  year: 2022
  ident: 7827_CR8
  publication-title: Microbiol. Immunol.
  doi: 10.1111/1348-0421.12945
– volume: 183
  start-page: 1024
  year: 2020
  ident: 7827_CR43
  publication-title: Cell
  doi: 10.1016/j.cell.2020.09.037
– volume: 29
  start-page: 463
  year: 2021
  ident: 7827_CR62
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2021.02.003
– volume: 19
  start-page: 155
  year: 2020
  ident: 7827_CR7
  publication-title: Nat. Rev. Microbiol.
  doi: 10.1038/s41579-020-00468-6
– volume: 19
  start-page: 679
  year: 2022
  ident: 7827_CR73
  publication-title: Nat. Methods
  doi: 10.1038/s41592-022-01488-1
– volume: 433
  start-page: 167177
  year: 2021
  ident: 7827_CR41
  publication-title: J. Mol. Biol.
  doi: 10.1016/j.jmb.2021.167177
– volume: 67
  start-page: 235
  year: 2011
  ident: 7827_CR71
  publication-title: Acta Crystallogr. Sect. D Biol. Crystallogr.
  doi: 10.1107/S0907444910045749
– volume: 593
  start-page: 130
  year: 2021
  ident: 7827_CR30
  publication-title: Nature
  doi: 10.1038/s41586-021-03398-2
– volume: 7
  start-page: 1863
  year: 2021
  ident: 7827_CR57
  publication-title: ACS Cent. Sci.
  doi: 10.1021/acscentsci.1c00804
– volume: 10
  start-page: 1
  year: 2019
  ident: 7827_CR23
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-019-11821-6
– volume: 583
  start-page: 290
  year: 2020
  ident: 7827_CR13
  publication-title: Nature
  doi: 10.1038/s41586-020-2349-y
– volume: 395
  start-page: 507
  year: 2020
  ident: 7827_CR2
  publication-title: Lancet
  doi: 10.1016/S0140-6736(20)30211-7
– volume: 581
  start-page: 215
  year: 2020
  ident: 7827_CR44
  publication-title: Nature
  doi: 10.1038/s41586-020-2180-5
– volume: 602
  start-page: 657
  year: 2022
  ident: 7827_CR16
  publication-title: Nature
  doi: 10.1038/s41586-021-04385-3
– volume: 108
  start-page: 193
  year: 1991
  ident: 7827_CR68
  publication-title: Gene
  doi: 10.1016/0378-1119(91)90434-D
– volume: 608
  start-page: 593
  year: 2022
  ident: 7827_CR19
  publication-title: Nature
  doi: 10.1038/s41586-022-04980-y
– volume: 117
  start-page: 7001
  year: 2020
  ident: 7827_CR10
  publication-title: Proc. Natl. Acad. Sci. Usa.
  doi: 10.1073/pnas.2002589117
– ident: 7827_CR18
  doi: 10.1016/j.chom.2022.10.003
– volume: 13
  start-page: 1
  year: 2022
  ident: 7827_CR26
  publication-title: Front. Immunol.
– volume: 35
  start-page: 109109
  year: 2021
  ident: 7827_CR48
  publication-title: Cell Rep
  doi: 10.1016/j.celrep.2021.109109
– volume: 369
  start-page: 1010
  year: 2020
  ident: 7827_CR14
  publication-title: Science (80-)
  doi: 10.1126/science.abd0827
– volume: 192
  start-page: 216
  year: 2015
  ident: 7827_CR78
  publication-title: J. Struct. Biol.
  doi: 10.1016/j.jsb.2015.08.008
– volume: 287
  start-page: 145
  year: 2020
  ident: 7827_CR33
  publication-title: FEBS J
  doi: 10.1111/febs.14991
– ident: 7827_CR11
  doi: 10.1038/s41467-020-15562-9
– volume: 184
  start-page: 92
  year: 2021
  ident: 7827_CR12
  publication-title: Cell
  doi: 10.1016/j.cell.2020.10.030
– volume: 588
  start-page: 327
  year: 2020
  ident: 7827_CR36
  publication-title: Nature
  doi: 10.1038/s41586-020-2772-0
– volume: 54
  start-page: 2385
  year: 2021
  ident: 7827_CR22
  publication-title: Immunity
  doi: 10.1016/j.immuni.2021.08.025
– volume: 579
  start-page: 270
  year: 2020
  ident: 7827_CR6
  publication-title: Nature
  doi: 10.1038/s41586-020-2012-7
– volume: 12
  start-page: 1
  year: 2021
  ident: 7827_CR46
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-020-20314-w
– volume: 14
  start-page: 793
  year: 2017
  ident: 7827_CR32
  publication-title: Nat. Methods
  doi: 10.1038/nmeth.4347
– volume: 28
  start-page: 445
  year: 2020
  ident: 7827_CR53
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2020.06.010
– volume: 14
  start-page: 290
  year: 2017
  ident: 7827_CR81
  publication-title: Nat. Methods
  doi: 10.1038/nmeth.4169
– volume: 31
  start-page: 25
  year: 2021
  ident: 7827_CR38
  publication-title: Cell Res
  doi: 10.1038/s41422-020-00444-y
– volume: 588
  start-page: 682
  year: 2020
  ident: 7827_CR25
  publication-title: Nature
  doi: 10.1038/s41586-020-2852-1
– volume: 37
  start-page: 734
  year: 2021
  ident: 7827_CR45
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/btaa739
– volume: 66
  start-page: 133
  year: 2010
  ident: 7827_CR70
  publication-title: Acta Crystallogr. Sect. D Biol. Crystallogr.
  doi: 10.1107/S0907444909047374
– ident: 7827_CR29
  doi: 10.1038/s41591-021-01294-w
– volume: 30
  start-page: 3373
  year: 2010
  ident: 7827_CR34
  publication-title: Anticancer Res
– volume: 584
  start-page: 120
  year: 2020
  ident: 7827_CR52
  publication-title: Nature
  doi: 10.1038/s41586-020-2381-y
– ident: 7827_CR58
  doi: 10.1128/JCM.01736-21
– volume: 5
  start-page: 1
  year: 2022
  ident: 7827_CR20
  publication-title: Commun. Biol.
  doi: 10.1038/s42003-022-03739-5
– volume: 54
  start-page: 1841
  year: 2021
  ident: 7827_CR28
  publication-title: Immunity
  doi: 10.1016/j.immuni.2021.06.015
– volume: 75
  start-page: 861
  year: 2019
  ident: 7827_CR75
  publication-title: Acta Crystallogr. Sect. D Struct. Biol.
  doi: 10.1107/S2059798319011471
– volume: 17
  start-page: 1
  year: 2021
  ident: 7827_CR61
  publication-title: PLoS Pathog
  doi: 10.1371/journal.ppat.1009772
– volume: 62
  start-page: 72
  year: 2006
  ident: 7827_CR69
  publication-title: Acta Crystallogr. Sect. D Biol. Crystallogr.
  doi: 10.1107/S0907444905036693
– volume: 367
  start-page: 1260
  year: 2020
  ident: 7827_CR37
  publication-title: Science (80-)
  doi: 10.1126/science.abb2507
– volume: 17
  start-page: 113
  year: 2021
  ident: 7827_CR39
  publication-title: Nat. Chem. Biol.
  doi: 10.1038/s41589-020-00679-1
– volume: 25
  start-page: 1605
  year: 2004
  ident: 7827_CR82
  publication-title: J. Comput. Chem.
  doi: 10.1002/jcc.20084
– volume: 27
  start-page: 293
  year: 2018
  ident: 7827_CR76
  publication-title: Protein Sci
  doi: 10.1002/pro.3330
– volume: 32
  start-page: 263
  year: 2024
  ident: 7827_CR55
  publication-title: Structure
  doi: 10.1016/j.str.2023.12.013
– volume: 20
  start-page: 512
  year: 2023
  ident: 7827_CR59
  publication-title: Nat. Methods
  doi: 10.1038/s41592-023-01769-3
– volume: 184
  start-page: 3205
  year: 2021
  ident: 7827_CR40
  publication-title: Cell
  doi: 10.1016/j.cell.2021.04.032
– volume: 385
  start-page: 46
  year: 2024
  ident: 7827_CR56
  publication-title: Science (80-)
  doi: 10.1126/science.adk8946
– volume: 369
  start-page: 1501
  year: 2020
  ident: 7827_CR31
  publication-title: Science (80-)
  doi: 10.1126/science.abd0826
SSID ssj0001999634
Score 2.2867694
Snippet Medical treatments using potent neutralizing SARS-CoV-2 antibodies have achieved remarkable improvements in clinical symptoms, changing the situation for the...
Abstract Medical treatments using potent neutralizing SARS-CoV-2 antibodies have achieved remarkable improvements in clinical symptoms, changing the situation...
SourceID doaj
pubmedcentral
proquest
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 483
SubjectTerms 631/326/596/4130
631/535/1258/1259
631/535/1266
631/61/51/2318
82/1
82/103
ACE2
Angiotensin-Converting Enzyme 2
Animals
Antibodies
Antibodies, Neutralizing - chemistry
Antibodies, Neutralizing - immunology
Antibodies, Neutralizing - therapeutic use
Antibodies, Viral - chemistry
Antibodies, Viral - immunology
Antibodies, Viral - therapeutic use
Biomedical and Life Sciences
COVID-19
COVID-19 - immunology
COVID-19 - therapy
COVID-19 - virology
COVID-19 Drug Treatment
Cricetinae
Cryoelectron Microscopy
Humans
Life Sciences
Medical treatment
Mesocricetus
SARS-CoV-2 - genetics
SARS-CoV-2 - immunology
Severe acute respiratory syndrome coronavirus 2
Spike Glycoprotein, Coronavirus - chemistry
Spike Glycoprotein, Coronavirus - genetics
Spike Glycoprotein, Coronavirus - immunology
Structure-function relationships
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELZQJSQuiJbXQlsZiRtYTWwnto-loqqQ4MBS1JvlJ-wlqbQpUvkr_bPMONntLgVx4RbFE3nkGWdm7JlvCHntYOWDzjVTlceSnNowhBljxnMwt20UrtTCfPzUnp3LDxfNxUarL8wJG-GBx4U7Kj3nKhWjl0GGXDtwmINpc3QiBTXWkYPN2wimyukK-vFCTlUyldBHS1nSsLB7K1pFxaotS1QA-__kZd5NlvztxrQYotNH5OHkQdLjkfNdci91e-T-2FPy-jG5mRdEWETToK6LFOvYpv8bXcQpN6iIg_aZdumqHHX8hKmAfFj4Pl7T3PcDzj7QqVBvSRfdEsN4fBh6ulG1dftVLMkg1H1zQDzQ-fHnOTvpvzJOf0BAjvk2T8j56fsvJ2ds6sDAgjRyYKHWrqmDhvBbJXCWuG-0UtmZ4DGaDb4x0kHI5cDm-Ri8aE2UjfNRpsZ7r8RTstP1XXpOaBTCZZF1iuDAaJ59rJzhlXLZKe5zNSNvVtKwlyPQhi0X5ELbUXYWZGeL7CxQv0OBrSkRJLu8ANWxk-rYf6nOjOyvxG2nnbu0AiHxsDk6DL9aD8Oew4sU16X-aqRpdQvGf0aejdqx5kQWkDwBHOotvdlidXukW3wvuN41eNtGN3pG3q5U7Javv6_Fi_-xFi_JA172hmCc75MdUNV0AO7W4A_LzvoFpcMqWg
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lb9QwELZgKyQuFW8CBRmJG1hNYid2TqitWlVIVKhLUW-RH3HZS1xIWqn8Ff4sM453l-V1i-KJ7HjGnhl75htCXmuYeat8wWRuMCWnaBjCjLHGlKBua8d1zIX5cFIfn4n359V5OnAbUljlck-MG7ULFs_IdzlClWHRavnu8ivDqlF4u5pKaNwmW7AFKzUjW_uHJx9P16csaM9zkbJlcq52BxHDsbCKK2pHyfINjRSB-_9mbf4ZNPnbzWlUSEf3yHayJOnexPr75FbXPyB3ptqSNw_Jj3lEhkVUDap7RzGfLe1zdOFSjFBkCw2e9t1VPPL4Dl0B-bgwwd1QH8KIvY80JewNdNEP6M7jwxjoL9lb669cDAqh-kID8Ujne6dzdhA-s5Jeg2OOcTePyNnR4aeDY5YqMTArGjEyWyhdFVaBGy47MJpKUykpvW6sQa_WmqoRGlwvDbrPOGt43ThRaeNEVxljJH9MZn3ou6eEOs615151DgwZVXrjct2UudRey9L4PCNvltxoLyfAjTZelHPVTrxrgXdt5F0L1PvIsBUlgmXHF-HbRZvWXhvLFubSOSOssL7Q4HPZpvZO887KXGZkZ8nuNq3goV3LW0ZerZph7eGFiu67cDXR1KoGIyAjTybpWI1ERLA8DiNUG3KzMdTNln7xJeJ7F2B1N6pSGXm7FLH1uP49F8_-_xvPyd0ySj1nZblDZiCE3QswqEbzMq2an0ScIs4
  priority: 102
  providerName: ProQuest
Title Structural and virological identification of neutralizing antibody footprint provides insights into therapeutic antibody design against SARS-CoV-2 variants
URI https://link.springer.com/article/10.1038/s42003-025-07827-0
https://www.ncbi.nlm.nih.gov/pubmed/40121330
https://www.proquest.com/docview/3180265417
https://www.proquest.com/docview/3180686036
https://pubmed.ncbi.nlm.nih.gov/PMC11929858
https://doaj.org/article/0059307ddb4c4cf1a642c96fda3ec707
Volume 8
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV1Lb9QwELZKKyQuiDcLZWUkbmCR2E7sHLerVtVKVKhLUW-WH3HZS4LYFKn8Ff4s40myy0I5cEoUT5SRZ5yZsWe-IeSNhZn3OuZMZS6V5OQVSzBjrHIczG0ZhMVamA9n5emFXFwWl3uEj7UwmLSPkJb4mx6zw96vJWZRpearyagpBmH6QYJqB90-mM0Wy8V2ZyX58EIOFTKZ0Le8vGOFEKz_Ng_z70TJP05L0QidPCD3B--Rznp-H5K9unlE7vb9JG8ek59LRINNSBrUNoGmGrbh30ZXYcgLQlHQNtKmvsZtjh_wKSDvVq4NNzS2bZe-3tGhSG9NV806hfDppmvpbxVb27cCJoJQe2WBuKPL2fmSzdvPjNPvEIynXJsn5OLk-NP8lA3dF5iXleyYz7Utcq8h9FY1OErcFVqpaCvvUiTrXVFJC-GWBXvngneirIIsrAuyLpxzSjwl-03b1M8JDULYKKKuAzgvmkcXMlvxTNloFXcxm5C3ozTM1x5kw-DhuNCml50B2RmUnQHqoySwDWUCyMYH7bcrMyiMwVaFmQrBSS99zC3EWb4qY7Ci9ipTE3I4itsMq3ZtRILDS43RYfj1ZhjWWzpEsU3dXvc0pS7B8E_Is147NpxIBMgTwKHe0ZsdVndHmtUXxPTOwdOudKEn5N2oYlu-_j0XL_6P_CW5x3EVCMb5IdkHpaxfgVPVuemwiuB6dHz28XxK7szL-RS3KH4BVuIj7Q
linkProvider Springer Nature
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQw0CpbIbgg3iwUMBKcIGpiO7FzQKgtrba0XaFui3pz_YjLXpJCUtDyK_wD38jYSXZZXrfeoniSTDwPz9jzQOi5gpk3wiURj7VPyUnyyJcZi3JNYLnNLFUhF-ZgnI2O2buT9GQF_ehzYXxYZa8Tg6K2lfF75OvUlyrzTav5m_NPke8a5U9X-xYaLVvsFbOv4LLVr3ffAn1fELKzfbQ1irquApFhOWsikwiVJkaAS8kLMACITgXnTuVGew_N6DRnCtwIBXpcW6NplluWKm1ZkWqtOYX3XkGrjGYxGaDVze3x-8PFro73HyjrsnNiKtZrFsK_fNdYvxrzKF5aAUOjgL9Zt38Gaf52UhsWwJ2b6EZnueKNltVuoZWivI2utr0sZ3fQ90moROureGBVWuzz5zq9iqe2i0kKbIArh8viImyxfINPAXgz1ZWdYVdVjf96g7sEwRpPy9pvH_iLpsK_ZIstnrIhCAWrMwXADZ5sHE6irepDRPAXBeJVNvVddHwpNLqHBmVVFg8QtpQqR50oLBhOgjhtY5WTmCunONEuHqKXPTXkeVvgQ4aDeSpkSzsJtJOBdhKgNz3B5pC-OHe4UX0-k52sy9AmMebWamaYcYkCH8_kmbOKFobHfIjWenLLTmPUcsHfQ_RsPgyy7g9wVFlUFy1MJjIwOobofssdc0xYKM5HAUOxxDdLqC6PlNOPoZ54AlZ-LlIxRK96Flvg9e-5ePj_33iKro2ODvbl_u547xG6ToIE0IiQNTQAhiwegzHX6CedBGF0etlC-xOFSWCZ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR3LbtQw0Cpbgbgg3iwUMBKcwJDYTuwcOCwtq3YLFWIp6s34EZe9JBVJQcuvcOc7GTvZXRbKgUNvUTyJR54Zz4w9D4Qea1h5K31KRGJCSk5akFBmjBSGgrrNHdMxF-btQb57yCdH2dEG-rnIhYlB-7GkZdymF9FhLxoeo6hC89Wg1ARJnp843wdT7pfzb-CqNS_3doCuTygdv_6wvUv6bgLE8oK3xKZSZ6mV4EqKEhQ_NZkUwuvCmuCZWZMVXIP7oGH_Ns4alheOZ9o4XmbGGMHgvxfQJtj3KR-gzdFoMp2sTnOC38B4n5WTMHkGwmuaLzYIOMuq_Ts4848b2qj4xlfRld5ixaNuja6hjbK6ji52PSznN9CPaaxAG6p3YF05HPLm-v0Uz1wfixTJj2uPq_I0Hq18h6kAvJ2Z2s2xr-s2zN7iPjGwwbOqCccG4aGt8W9ZYquvXAw-wfpYA3CLp6P3U7JdfyQUf9UgVlXb3ESH50KjW2hQ1VV5B2HHmPbMy9KBwSSpNy7RBU2E9lpQ45MherqghjrpCnuoeCHPpOpop4B2KtJOAfSrQLAlZCjKHV_UX45Vz6QqtkdMhHOGW259qsG3s0XunWalFYkYoq0FuVW_UzSKhRJ8oRk7DD9aDoOMh4sbXZX1aQeTyxyMjSG63XHHEhMei_IxwFCu8c0aqusj1exzrCOegnVfyEwO0bMFi63w-vda3P0_8Ifo0rudsXqzd7B_D12mUSAYoXQLDYA_y_tg07XmQS9QGH06bxn-BZhmX3k
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Structural+and+virological+identification+of+neutralizing+antibody+footprint+provides+insights+into+therapeutic+antibody+design+against+SARS-CoV-2+variants&rft.jtitle=Communications+biology&rft.au=Anraku%2C+Yuki&rft.au=Kita%2C+Shunsuke&rft.au=Onodera%2C+Taishi&rft.au=Sato%2C+Akihiko&rft.date=2025-03-22&rft.pub=Nature+Publishing+Group+UK&rft.eissn=2399-3642&rft.volume=8&rft_id=info:doi/10.1038%2Fs42003-025-07827-0&rft.externalDocID=PMC11929858
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2399-3642&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2399-3642&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2399-3642&client=summon